Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections
Shots:
- The NMPA has approved the IND application of SPR206 (IV) for the treatment of MDR gram-negative bacterial infections. Everest will initiate the clinical program in China & results from the P-I study is expected in 2022
- Everest got exclusive rights to develop- manufacture & commercialize SPR206 in China- South Korea- and Southeast Asian countries for the same indication under the license agreement with Spero
- Spero has reported the results from its P-I SAD & MAD clinical trial for SPR206 which showed that the therapy is well-tolerated with no evidence of nephrotoxicity at doses within the anticipated therapeutic range for MDR gram-negative bacterial infections
Ref: PR Newswire | Image: Everest Medicines
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
